DTX2

Across TCGA pan-cancer cohorts, DTX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DTX2 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DTX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DTX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where DTX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.771	0.237	.002	37	view →
HNSC	OS	Median	II,III,IV	0.991	0.936	.033	5	view →
CCRCC	OS	Tertile	All	0.623	1.000	.031	4	view →
PDAC	OS	Quartile	All	0.474	0.647	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DTX2–LUAD (DFS)

Open the LUAD breakdown →